Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YUflyma® (Adalimumab), Patient Experience After Switching to adaliMumab biosimilAr High concenTration, Low Volume (40mg/0.4mL) (Yuflyma®) by Taking Patient pERception of Treatment Into Account: The YU-MATTER Study

Next Previous
Search
Trial Profile

YUflyma® (Adalimumab), Patient Experience After Switching to adaliMumab biosimilAr High concenTration, Low Volume (40mg/0.4mL) (Yuflyma®) by Taking Patient pERception of Treatment Into Account: The YU-MATTER Study

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis; Axial spondyloarthritis; Crohn's disease; Inflammatory bowel diseases; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis; Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms YU-MATTER Study
  • Sponsors Celltrion

    • Most Recent Events

    • 15 Jun 2024 Primary endpoint (Overall satisfaction) has been met, according to the results presented at the 25th Annual Congress of the European League Against Rheumatism.
    • 15 Jun 2024 Results (n=232) assessing the overall improvement in injection tolerance after switching to CT-P17, presented at the 25th Annual Congress of the European League Against Rheumatism
    • 15 Jun 2024 Results assessing patient beliefs about medicine and health knowledge that may impact patients satisfaction after a switch to a BioS of adalimumab. , presented at the 25th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top